MindMed's Phase 2b Trial For MM-120 In GAD Reaches Enrollment Milestone
Portfolio Pulse from The Dales Report
MindMed (NASDAQ:MNMD) has completed the enrollment and dosing phase of its Phase 2b trial, Study MMED008, which is researching the effectiveness of MM-120 in treating Generalized Anxiety Disorder (GAD). The trial recruited 198 participants across 20 clinical sites. The primary objective of the study is to establish the dose-response correlation among four MM-120 doses compared to a placebo. Top-line results are expected in Q4 2023.
September 12, 2023 | 4:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
MindMed's completion of the enrollment phase for its Phase 2b trial of MM-120 could potentially bring the company closer to a new treatment for GAD. This could have a positive impact on the company's stock in the short term.
The completion of the enrollment phase for MindMed's Phase 2b trial of MM-120 is a significant milestone for the company. If the trial results are positive, it could potentially lead to a new treatment for GAD, which could increase the company's market share and revenue, positively impacting the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100